172927-65-0
172927-65-0 結構式
基本信息
WBNUCLPUOSXSNJ-UHFFFAOYSA-N
Acetic acid, 2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-10309 | 化合物 T28775 Sibrafiban | 172927-65-0 | 1 mg | 950元 |
| 2026/06/05 | HY-10309 | 化合物 T28775 Sibrafiban | 172927-65-0 | 5 mg | 2400元 |
| 2026/06/05 | HY-10309 | 化合物 T28775 Sibrafiban | 172927-65-0 | 10 mM * 1 mLin DMSO | 2640元 |
常見問題列表
Glycoprotein IIb/IIIa receptor
The effects of site occupancy by Sibrafiban on platelet activation are assessed using P-selectin expression, fibrinogen binding and microaggregate formation. Sibrafiban inhibits ADP and TRAP-stimulated fibrinogen binding and microaggregate formation in a concentration-dependent manner, whereas P-selectin expression is relatively unaltered. A decrease in site occupancy from peak to trough of Sibrafiban does not result in increased activation of platelets.
The effects of Ro 44-3888 on the platelet aggregation response to ADP (17 μmol) and on cutaneous bleeding times is determined in 8 rhesus monkeys given Sibrafiban 0.25 mg/kg/day or 0.5 mg/kg/day orally for 8 days. The maximum inhibition of ex vivo platelet aggregation and prolongation of bleeding time by Ro 44-3888 are dose dependent.